AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 DEC 5 - (NewsRx.com & NewsRx.net) -- New data adds to existing evidence that Taxol offers women with metastatic breast cancer (MBC) a 31% improvement in overall survival compared with standard treatment.
The data collected from 640 patients treated in a consecutive series of studies between 1994 and 2001 also showed an improvement in tumor shrinkage when treated with Taxol-based chemotherapy.
"This study in effect demonstrates treatment outcomes before and after the advent of paclitaxel because we have analyzed data over an extensive period of time. These results clearly show the dramatic impact that paclitaxel has had on improving the quality of care for our patients," said Professor Pier Franco Conte, lead investigator of the study, division of medical oncology, St. Chiara University Hospital, Pisa, Italy,
He added, "These highly significant survival results must surely lead us to adopt paclitaxel as a first line treatment for women with metastatic breast cancer."
Analysis of data collected from six studies involving 640 women with MBC showed that the 291 patients receiving epirubicin plus Taxol (ET) as first line treatment had a 31% reduction in the hazard of death and a 33% reduction in the hazard of disease progression on top of that seen with the 349 patients who received 5-fluorouracil, epirubicin, cyclophosphamide (FEC), the standard combination currently used to treat women with MBC.
The median ...
Source: HighBeam Research, Paclitaxel-based chemotherapy increases survival by 31%.(breast...